JP2012197276A - 皮膚病の治療用組成物、並びにそれを用いた製剤及びその調製方法 - Google Patents
皮膚病の治療用組成物、並びにそれを用いた製剤及びその調製方法 Download PDFInfo
- Publication number
- JP2012197276A JP2012197276A JP2012064489A JP2012064489A JP2012197276A JP 2012197276 A JP2012197276 A JP 2012197276A JP 2012064489 A JP2012064489 A JP 2012064489A JP 2012064489 A JP2012064489 A JP 2012064489A JP 2012197276 A JP2012197276 A JP 2012197276A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- composition
- skin
- unsaturated fatty
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 208000017520 skin disease Diseases 0.000 title claims abstract description 23
- 238000009472 formulation Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 9
- 206010048768 Dermatosis Diseases 0.000 title claims abstract 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 30
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 30
- 102000008186 Collagen Human genes 0.000 claims abstract description 24
- 108010035532 Collagen Proteins 0.000 claims abstract description 24
- 229920001436 collagen Polymers 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 20
- 229940088594 vitamin Drugs 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 235000013343 vitamin Nutrition 0.000 claims abstract description 15
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 24
- 229940024606 amino acid Drugs 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 16
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 13
- 235000019155 vitamin A Nutrition 0.000 claims description 13
- 239000011719 vitamin A Substances 0.000 claims description 13
- 229940045997 vitamin a Drugs 0.000 claims description 13
- 229930003427 Vitamin E Natural products 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- 229940046009 vitamin E Drugs 0.000 claims description 12
- 235000019165 vitamin E Nutrition 0.000 claims description 12
- 239000011709 vitamin E Substances 0.000 claims description 12
- 235000013311 vegetables Nutrition 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 8
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 7
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 7
- 159000000000 sodium salts Chemical group 0.000 claims description 7
- 239000004520 water soluble gel Substances 0.000 claims description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 229960002969 oleic acid Drugs 0.000 claims description 4
- 235000021313 oleic acid Nutrition 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 229960004232 linoleic acid Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 206010000496 acne Diseases 0.000 abstract description 13
- 201000004681 Psoriasis Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 150000003839 salts Chemical class 0.000 abstract description 7
- 201000009053 Neurodermatitis Diseases 0.000 abstract description 2
- 208000010195 Onychomycosis Diseases 0.000 abstract description 2
- 239000000945 filler Substances 0.000 abstract description 2
- 201000004647 tinea pedis Diseases 0.000 abstract description 2
- 201000005882 tinea unguium Diseases 0.000 abstract description 2
- 208000003643 Callosities Diseases 0.000 abstract 1
- 206010020649 Hyperkeratosis Diseases 0.000 abstract 1
- 206010034016 Paronychia Diseases 0.000 abstract 1
- 241000029132 Paronychia Species 0.000 abstract 1
- 206010067197 Tinea manuum Diseases 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- 239000002674 ointment Substances 0.000 description 14
- 208000002874 Acne Vulgaris Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 241000251468 Actinopterygii Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000001103 potassium chloride Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- 210000004927 skin cell Anatomy 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- -1 lysine Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000241413 Propolis Species 0.000 description 4
- 206010037888 Rash pustular Diseases 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 229940069949 propolis Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000238413 Octopus Species 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 239000010495 camellia oil Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】本発明に係る皮膚病の治療用組成物は、不飽和脂肪酸、コラーゲン、アミノ酸、ビタミン及び無機塩を含む。
【選択図】 なし
Description
(1)上記製剤の組成に従って原料を取る、
(2)コラーゲンおよび水溶性原料を溶解させて水溶性ゲルマトリックスを得る。ここで、水溶性原料はアミノ酸、ビタミン及び無機塩である、
(3)不飽和脂肪酸中に賦形剤と適量の界面活性剤を加え、均一に混合させた後、ステップ(2)で得られた水溶性ゲルマトリックスを徐々に加え、均一に乳化させることにより、軟膏剤又は液剤を得る、
(4)最終製品に仕上げて包装する。
以下の組成と割合に従って原料を取った。まずは、オリーブ油を凝結させてから高速遠心して不飽和脂肪酸を精製した。精製された不飽和脂肪酸を65g、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリンの混合物を2g、精製した魚鱗コラーゲンペプチドを5g、塩化ナトリウムを0.9g、塩化カリウムを0.1g、ビタミンEを0.1g、ビタミンAを0.1g使用し、その中にプロポリスを25g、植物性香料を1.8g加えた。次いで、コラーゲン、アミノ酸及び無機塩を水に溶解させることで、水溶性ゲルマトリックスを得た。次いで、ビタミンを溶解させた不飽和脂肪酸中へ25gのプロポリスを加え、均一になるまで混合し、その後その中に上記水溶性ゲルマトリックスを徐々に加え、均一に乳化することにより、軟膏剤を得た。最終製品に仕上げて包装した。
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製したオリーブ油を70g、魚鱗コラーゲンペプチドを0.1g、リジンなどの8種のアミノ酸の混合物を0.1g、ビタミンAを0.05g、ビタミンEを0.05g、NaClを0.05g、プロポリスを25g、及び植物性香料を4.65gとした。
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製した菜種油を65g、魚鱗コラーゲンペプチドを10g、リジンなどの8種のアミノ酸の混合物を6g、ビタミンAを3.5g、ビタミンEを3.5g、NaClを0.5g、KClを0.1g、プロポリスを10g、及び植物性香料を1.4gとした。
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製したひまわり油60g、魚鱗コラーゲンペプチドを5.5g、リジンなどの8種のアミノ酸の混合物を1.5g、ビタミンAを2.0g、ビタミンEを1.5g、NaClを0.4g、KClを0.1g、ワセリンを24g、及び植物性香料:5gとした。
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製した茶油を55g、魚鱗コラーゲンペプチドを8g、リジンなどの8種のアミノ酸の混合物を3g、ビタミンAを3.0g、ビタミンEを2.0g、NaClを0.9g、KClを0.1g、ワセリンを25g、及び植物性香料を3gとした。
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製したオリーブ油を50g、魚鱗コラーゲンペプチドを10g、リジンなどの8種のアミノ酸の混合物を6g、ビタミンAを3.5g、ビタミンEを3.5g、NaClを0.9g、KClを0.1g、ワセリンを22g、及び植物性香料を4.0gとした。
以下の組成と割合に従って原料を取った。まずは、オリーブ油を凝結させてから高速遠心して不飽和脂肪酸を精製した。精製後の不飽和脂肪酸を80g、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリンの混合物を6g、魚鱗コラーゲンペプチドを10g、塩化ナトリウムを0.9g、塩化カリウムを0.1g、ビタミンEを1.5g、ビタミンAを1.5g使用した。次いで、コラーゲン、アミノ酸及び無機塩を水に溶解させることで、水溶性ゲルマトリックスを得た。次いで、ビタミンを溶解させた不飽和脂肪酸中に上記水溶性ゲルマトリックスを徐々に加え、均一に乳化させることにより、液剤を得た。このように、最終製品に仕上げて包装した。
実施例1又は実施例7に記載の製品を単層の薄膜状の下地に塗布し、マスクに加工した後パッケージする。上記薄膜状下地は純綿、不織布又は合成繊維材料を用いる。
本発明に係る製剤は、臨床に大きく応用され、効果的なフィードバックが得られた。即ち、臨床応用において、皮膚血液循環の改善、肌の免疫力と皮膚の栄養状態の強化、角質層の柔軟化、顔色の改善及び色素吸収の促進等の役割があり、毛穴を閉塞する角質層、重金属及び化学汚染物の除去、輻射の防止、皮膚への栄養供給ができる。また、活性栄養物質と栄養成分に富み、すぐに皮膚に浸透し皮膚細胞に欠けた栄養を迅速に補充でき、即効性がある。また、毛穴を縮め、細胞再生を増強し、皮膚に必要な栄養を補充し、細胞自身の免疫力を向上させることができる。本発明に係る製剤を用いて皮膚病を治療した臨床観察実験は以下に示す。
乾癬患者合計40例で、全病例をランダムに対照群と実験群に分け、1群は20例である。
対照群患者の皮膚に、臨床常用のグルココルチコイドを昼夜各1回塗布し、7日間後、アジスロマイシン軟膏(azithromycin cream)の塗布を始め、それを1日3回行った。実験群患者の発症部位に、本発明の実施例1の軟膏剤を昼夜各1回塗布した。そして、実験開始の7日目、1ヶ月目、2ヶ月目に、2群の患者の皮膚の回復状況をそれぞれ観察した。
対照群患者は、グルココルチコイドを使用した7日間後、皮膚がよくなり滑らかとなりはじめた。7日間後、グルココルチコイドの代わりにアジスロマイシン軟膏を使用し、3週間治療し続けた。治療開始の1ヶ月後、乾癬の一部の鱗屑が柔らかになり剥がれ始めた。治療開始の2ヶ月後、治療開始の1ヶ月の時と比べて、治療状況はあまり差がなく、患者の乾癬が改善したが、完治した患者がいない。
にきび患者合計50例で、全病例をランダムに対照群と実験群に分け、1群は25例である。
対照群患者に、臨床常用の薬であるイソトレチノインを1日2回経口投与し、実験群患者の発症部位に、本発明の軟膏剤を昼夜各1回塗布した。そして、実験開始の2日目、7日目、2週間目に、2群の患者の皮膚の回復状況をそれぞれ観察した。
対照群患者には、イソトレチノインを経口投与した2日間後、皮膚が良くなった。経口投与した7日間後、以前より皮膚の改善にあまり効果がなかった。経口投与した2週間後、治療開始の1週間の時と比べて、治療状況はあまり差がなく、患者のにきびが改善したが、完治した患者がいない。
臨床ケース1:李××、男、61歳、年中運転しているので、足部に鶏眼ができたが、本製品を使用した二週間後、鶏眼が柔軟となり始め、二ヵ月後剥がれて完治した。同時に、本製品を使用して老人斑を治療し、一ヵ月後、大部分の老人斑が浅くなり、一部が消えた。
Claims (10)
- 不飽和脂肪酸、コラーゲン、アミノ酸、ビタミン及び無機塩を含むことを特徴とする皮膚病の治療用組成物。
- 前記不飽和脂肪酸は、アラキドン酸、オレイン酸、リノレン酸、及びリノール酸からなる群から選ばれる一種以上であることを特徴とする請求項1に記載の皮膚病の治療用組成物。
- 前記アミノ酸は、グルタミン酸、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリン、ヒスチジン、及びアルギニンからなる群から選ばれる一種以上であることを特徴とする請求項1に記載の皮膚病の治療用組成物。
- 前記ビタミンはビタミンE及び/又はビタミンAであることを特徴とする請求項1に記載の皮膚病の治療用組成物。
- 前記無機塩はナトリウム塩及び/又はカリウム塩であることを特徴とする請求項1に記載の皮膚病の治療用組成物。
- 前記組成物の中、重量%で、不飽和脂肪酸含有量が65%〜90%であることを特徴とする請求項1に記載の皮膚病の治療用組成物。
- 各成分の含有量は、重量%で、不飽和脂肪酸が50%〜70%、コラーゲンが0.1%〜10%、アミノ酸が0.1%〜6%、ビタミンが0.1%〜7%、無機塩が0.05%〜1%、賦形剤が10%〜25%、及び植物性香料が1%〜5%であることを特徴とする皮膚病の治療用製剤。
- 前記ビタミンは、0.1%〜1%のビタミンEと0.1%〜1%のビタミンAを含むことを特徴とする請求項7に記載の皮膚病の治療用製剤。
- 前記無機塩は、0.05%〜0.9%のナトリウム塩と0.05%〜0.1%のカリウム塩を含むことを特徴とする請求項7に記載の皮膚病の治療用製剤。
- 前記製剤の組成に従って原料を取るステップと、
コラーゲンおよび水溶性原料を溶解させて、水溶性ゲルマトリックスを得るステップと、
不飽和脂肪酸に賦形剤を加え、均一に混合させた後、他の原料を徐々に加え、均一に乳化させることにより、製剤を得るステップと、
最終製品に仕上げて包装するステップと、を含むことを特徴とする請求項7に記載の皮膚病の治療用製剤の調製方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110068644.0 | 2011-03-22 | ||
CN201110068644.0A CN102688483B (zh) | 2011-03-22 | 2011-03-22 | 一种治疗皮肤病的组合物、含有该组合物的制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012197276A true JP2012197276A (ja) | 2012-10-18 |
JP5622775B2 JP5622775B2 (ja) | 2014-11-12 |
Family
ID=46854326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012064489A Expired - Fee Related JP5622775B2 (ja) | 2011-03-22 | 2012-03-21 | 皮膚病の治療用組成物、並びにそれを用いた製剤及びその調製方法 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5622775B2 (ja) |
KR (1) | KR101445730B1 (ja) |
CN (1) | CN102688483B (ja) |
HK (1) | HK1161510A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019101A (ja) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
JP2019019100A (ja) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104367992A (zh) * | 2014-10-20 | 2015-02-25 | 广西壮族自治区花红药业股份有限公司 | Ⅰ型胶原蛋白在制备治疗和/或预防银屑病药物方面的新用途 |
CN106902388A (zh) * | 2015-12-22 | 2017-06-30 | 上海邦中高分子材料有限公司 | 一种3d打印生物纸及其制备方法和用途 |
CN108355130A (zh) * | 2018-05-22 | 2018-08-03 | 界首市菁华科技信息咨询服务有限公司 | 一种治疗牛皮癣的温敏型胶原复合消炎凝胶喷剂及其制备方法 |
CN114177348B (zh) * | 2021-12-14 | 2023-02-10 | 华北理工大学 | 一种医用液体敷料及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002520348A (ja) * | 1998-07-15 | 2002-07-09 | マンドルロ インヴェストメント ゲーエムベーハー | 皮膚と組織の保護、および/または治療用薬剤 |
JP2010248148A (ja) * | 2009-04-17 | 2010-11-04 | Rohto Pharmaceut Co Ltd | アドバンスド・グリケーション・エンド・プロダクツ分解剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU693312B2 (en) * | 1995-01-18 | 1998-06-25 | Taisho Pharmaceutical Co., Ltd. | Remedy for dermatitis |
WO1998052927A1 (en) | 1997-05-19 | 1998-11-26 | Rosemarie Scivoletto | Composition for treating skin conditions |
CU22693A1 (es) * | 1999-02-22 | 2001-07-31 | Ct De Histoterapia Placentaria | Composición para el tratamiento de la psoriasis y método para su obtención |
CN1270160A (zh) * | 1999-04-14 | 2000-10-18 | 李文光 | 精制多不饱和脂肪酸及多不饱和脂肪酸钙药用制品、制备工艺及制剂 |
JP2002047123A (ja) | 2000-08-02 | 2002-02-12 | Asahi Kasei Corp | 香粧品 |
CN1357314A (zh) * | 2000-12-12 | 2002-07-10 | 长沙市海人生物科技有限公司 | 温泉生物活性浴剂 |
EP2340856B2 (de) | 2003-05-24 | 2017-11-15 | La Prairie Group AG | Kosmetische oder dermatologische Zubereitung umfassend eine Nährmedienphase |
CN101168104B (zh) | 2007-08-21 | 2011-11-02 | 天津天大天久科技股份有限公司 | 大型填料塔器中的气液分布装置 |
-
2011
- 2011-03-22 CN CN201110068644.0A patent/CN102688483B/zh not_active Expired - Fee Related
-
2012
- 2012-03-08 HK HK12102381.9A patent/HK1161510A2/xx not_active IP Right Cessation
- 2012-03-19 KR KR1020120027771A patent/KR101445730B1/ko active IP Right Grant
- 2012-03-21 JP JP2012064489A patent/JP5622775B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002520348A (ja) * | 1998-07-15 | 2002-07-09 | マンドルロ インヴェストメント ゲーエムベーハー | 皮膚と組織の保護、および/または治療用薬剤 |
JP2010248148A (ja) * | 2009-04-17 | 2010-11-04 | Rohto Pharmaceut Co Ltd | アドバンスド・グリケーション・エンド・プロダクツ分解剤 |
Non-Patent Citations (5)
Title |
---|
JPN6013053549; 日本臨床 vol.51, no.4, 1993, p.197-202 * |
JPN6013053551; 医学と薬学 vol.41, no.6, 1999, p.1111-1115 * |
JPN6013053554; Annals of allergy vol.10, no.6, 1952, p.703-4 * |
JPN6013053556; 愛知県病院薬剤師会雑誌 vol.25, 1997, p.13-17 * |
JPN6013053557; Int J Dermatol vol.20, no.9, 1981, p.616 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019101A (ja) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
JP2019019100A (ja) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
JP7343885B2 (ja) | 2017-07-20 | 2023-09-13 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
Also Published As
Publication number | Publication date |
---|---|
CN102688483A (zh) | 2012-09-26 |
KR101445730B1 (ko) | 2014-10-01 |
JP5622775B2 (ja) | 2014-11-12 |
KR20120107864A (ko) | 2012-10-04 |
HK1161510A2 (en) | 2012-07-27 |
CN102688483B (zh) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5622775B2 (ja) | 皮膚病の治療用組成物、並びにそれを用いた製剤及びその調製方法 | |
JP6495183B2 (ja) | 表面の創傷を処置するための組成物および方法 | |
US11058735B2 (en) | Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract | |
PT1853303E (pt) | Composições estabilizadas para administração tópica, e métodos para a sua preparação | |
JP2011088930A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP2023516616A (ja) | 製剤およびその使用 | |
EP0531495A1 (en) | THERAPEUTIC AND COSMETIC COMPOSITIONS FOR SKIN TREATMENT. | |
JP5643872B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
CN108210584A (zh) | 消炎止痛快速愈合外用中药制剂及其制备方法 | |
JP5164438B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP5699184B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
EP2692332B1 (en) | Composition for the treatment of callus, corns and psoriasis | |
WO2016144196A1 (en) | A pharmaceutical and/or cosmetic composition for treating skin diseases and damages, the process for preparing of the pharmaceutical and/or cosmetic composition and its use | |
WO2015168224A1 (en) | Synergistic mixture of betamethasone and tranilast with a transdermal gel for scar treatment | |
CN112316108B (zh) | 促进及治疗慢性伤口愈合的组合物和方法 | |
CN105982882B (zh) | 一种光学活性原料组合物组方治疗痔疮的外用药及制备工艺 | |
CN113713000B (zh) | 用于治疗疮痈、烧烫伤和痤疮的主药成分组合物、缓控释药物制剂及其制备方法和应用 | |
KR101607229B1 (ko) | 말기름을 함유하는 상처 치료용 조성물 | |
JP5993336B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
KR20100111061A (ko) | 상처 치료용 조성물 | |
RU2500409C2 (ru) | Лечебно-косметическое средство | |
CN106581663A (zh) | 一种治疗激素依赖性皮炎的组合物 | |
Surana et al. | Updated Review on: Cucurbita Maxima (Pumpkin Seed) oil for acne relief patches | |
JP2013177461A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
TWI325324B (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20130605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140127 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140430 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140724 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140922 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5622775 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |